Navigation Links
Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
Date:8/16/2012

ALLEGAN, Mich., Aug. 16, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Perrigo's Chairman and CEO Joseph C. Papa commented, "For the sixth straight year, we delivered year-over-year record sales and earnings while continuing to make investments in our facilities and production processes which we believe will further enhance our own already high standards of excellent product quality. During this fiscal year, we also announced the acquisition of CanAm Care to broaden our diabetes category offerings, multiple supply agreements for infant formula in China and numerous new product launches. The penetration of store brand share in the U.S. market continues to gain momentum as retailers and patients continue to turn to high quality, affordable alternatives for their healthcare needs. We look forward to another great year, with many new products in the pipeline across all segments."

Refer to Table I at the end of this press release for adjustments in the current year and prior year periods and additional non-GAAP disclosure information.

The Company's reported results are summarized in the attached Consolidated Statements of Income, Balance Sheets and Cash Flows.Perrigo Company
(from continuing operations, in thousands, except per share amounts)
(see the attached Table I for reconciliation to GAAP numbers)

 Fourth Quarter

Fiscal Year2012

2011

2012

2011Net Sales

$831,767

$704,629

$3,173,249

$2,755,029Reported Income

$107,050

$85,570

$392,974

$340,558Adjusted Income

$120,946

$95,418
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
2. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
5. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
7. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
8. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. Discovery Labs Reports Second Quarter 2012 Financial Results
10. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
11. Cambrex Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, ... of an agreement with Novella Clinical (Novella), ... in patients with newly diagnosed glioblastoma. Novella is a ... services to small to mid-sized oncology companies. The ICT-107 ... in the US, Europe and ...
(Date:7/3/2015)... ... ... global failure analysis market is expected to reach $7,147.0 million by 2020, at a ... at the highest CAGR of 8.46%; its growth is expected to be driven by ... for root cause analysis of failure. The market based on the geographic regions has ...
(Date:7/2/2015)... , ... July 03, 2015 , ... Cuvettes have been used in countless labs for ... to find the cuvette they needed. As expected, this was a daunting and tiring ... wrong part because they were not able to navigate the complex catalog structure. , Now ...
(Date:7/2/2015)... ... 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ), ... today the acquisition of Turner Medical, Inc ., thus becoming a global ... the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s product ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... efforts of two kinds of bacteria to produce hydrogen in ... the other. According to an article in the August issue ... bonus: leftover enzymes can be used to scavenge precious metals ... convert hydrogen into energy. , Hydrogen has three times more ...
... 6, 2008 TIME: 9:30 ... Dr. Candace Kendle, Chairman and CEO, Kendle (Nasdaq: KNDL ... Aug. 6 at 9:30 a.m. Eastern Time to,discuss its financial results ... session will follow., Webcast Instructions, To access the live ...
... (Nasdaq: SGMO ) today announced that the company ... July 23,2008, after the market closes. The press release ... PT, which will be open to the public via,telephone ... review,the financial results and discuss other business matters., ...
Cached Biology Technology:Fuel from food waste: bacteria provide power 2Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 3
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... 2013 -- A test that measures the expression levels ... effectively differentiate between patients who are at higher and ... the body more than five years after diagnosis, researchers ... individual risk prediction for women with these cancers is ...
... have been bombarded by stories in the media and on ... levels, and urging high doses of supplements to protect against ... But new research from Johns Hopkins finds that blood ... of the range suggested by the Institute of Medicine confer ...
... experimental drug has shown promise in treating influenza, preventing lung ... to University of Maryland School of Medicine researchers publishing in ... found that a drug called Eritoran can protect mice from ... of influenza virus. The potential value of this drug as ...
Cached Biology News:Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 2Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence 3Vitamin D: More may not be better 2University of Maryland School of Medicine researchers find potential novel treatment for influenza 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
...
Biology Products: